U.S. markets closed

23andMe Holding Co. (ME)

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD.
Añadir a la lista de seguimiento
0.4432-0.0184 (-3.99%)
Al cierre: 04:00PM EDT
0.4501 +0.01 (+1.56%)
Fuera de horario: 07:24PM EDT

23andMe Holding Co.

349 Oyster Point Boulevard
South San Francisco, CA 94080
United States
650 938 6300

IndustriaDiagnostics & Research
Empleados a tiempo completo769

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Ms. Anne WojcickiCo-Founder, CEO, President & Chair of the Board62.92kN/DN/D
Mr. Joseph SelsavageInterim CFO & Accounting Officer574.56kN/D1963
Mr. Guy ChayounVP, Interim General Counsel & Corporate SecretaryN/DN/DN/D
Ms. Katie WatsonVice President of CommunicationsN/DN/D1978
Mr. Jonathan WardChief Marketing OfficerN/DN/DN/D
Mr. Reza Afkhami M.B.A.Chief Corporate Development OfficerN/DN/DN/D
Ms. Savita PillaiVice President of PeopleN/DN/DN/D
Dr. Jennifer LowHead of Therapeutics DevelopmentN/DN/D1969
Mr. Kent HillyerVice President of Consumer OperationsN/DN/D1968
Mr. Daniel ChuChief Product OfficerN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.


23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.

Gestión corporativa

La calificación ISS Governance QuickScore de 23andMe Holding Co. a partir del 1 de abril de 2024 es 9. Las puntuaciones principales son Auditoría: 3; Junta: 8; Derechos del accionista: 10; Compensación: 8.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.